trastuzumab deruxtecan,ruxolitinib,Trastuzumab,Tucatinib
novartis,daiichi sankyo,astrazeneca,incyte,seagen
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'mountaineer', 'combine,egfr,i', 'destiny,crc,02', 'combine,egfr,1']
. combines our understanding of mountaineer &amp; destiny-crc02 in her2-mutant mcrc at #asco23 1. prior anti-her2 therapy does not preclude benefit
2. neither does ras mutation (as opposed to anti-egfr mab)
3. clinically meaningful responses seen at ihc2+ (not just 3+)
Director, GI Oncology, @Intermountain. Interests: neuroendocrine tumors, cancer syndromes, empathy (even had a Whipple myself). Tweets my own.